Reuters logo
BRIEF-Merck's doravirine meets primary efficacy endpoint in pivotal phase 3 trial
February 14, 2017 / 9:45 PM / 9 months ago

BRIEF-Merck's doravirine meets primary efficacy endpoint in pivotal phase 3 trial

Feb 15 (Reuters) - Merck & Co Inc :

* Merck’s doravirine, an investigational non-nucleoside reverse transcriptase inhibitor (nnrti) for the treatment of hiv-1 infection, met primary efficacy endpoint in pivotal phase 3 trial

* Merck’s doravirine, an investigational non-nucleoside reverse transcriptase inhibitor (nnrti) for the treatment of hiv-1 infection, met primary efficacy endpoint in pivotal phase 3 trial

* Merck - data presented at croi showed doravirine was non-inferior to ritonavir-boosted darunavir in treatment-naïve adults after 48 weeks of treatment

* Says study met its primary efficacy endpoint

* Merck & Co - secondary endpoint showed that dor-treated group had statistically significant lower levels of fasting low density lipoprotein cholesterol Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below